全文获取类型
收费全文 | 17852篇 |
免费 | 1452篇 |
国内免费 | 85篇 |
专业分类
耳鼻咽喉 | 223篇 |
儿科学 | 510篇 |
妇产科学 | 295篇 |
基础医学 | 2262篇 |
口腔科学 | 258篇 |
临床医学 | 1954篇 |
内科学 | 4471篇 |
皮肤病学 | 231篇 |
神经病学 | 1289篇 |
特种医学 | 649篇 |
外科学 | 2791篇 |
综合类 | 260篇 |
一般理论 | 9篇 |
预防医学 | 1249篇 |
眼科学 | 624篇 |
药学 | 1082篇 |
中国医学 | 47篇 |
肿瘤学 | 1185篇 |
出版年
2023年 | 82篇 |
2021年 | 234篇 |
2020年 | 184篇 |
2019年 | 351篇 |
2018年 | 357篇 |
2017年 | 297篇 |
2016年 | 298篇 |
2015年 | 329篇 |
2014年 | 503篇 |
2013年 | 753篇 |
2012年 | 1065篇 |
2011年 | 1033篇 |
2010年 | 639篇 |
2009年 | 626篇 |
2008年 | 1065篇 |
2007年 | 1128篇 |
2006年 | 1154篇 |
2005年 | 1092篇 |
2004年 | 1064篇 |
2003年 | 1014篇 |
2002年 | 946篇 |
2001年 | 299篇 |
2000年 | 280篇 |
1999年 | 238篇 |
1998年 | 182篇 |
1997年 | 156篇 |
1996年 | 122篇 |
1995年 | 191篇 |
1994年 | 150篇 |
1993年 | 118篇 |
1992年 | 204篇 |
1991年 | 167篇 |
1990年 | 169篇 |
1989年 | 160篇 |
1988年 | 171篇 |
1987年 | 161篇 |
1986年 | 142篇 |
1985年 | 124篇 |
1984年 | 129篇 |
1983年 | 137篇 |
1982年 | 134篇 |
1981年 | 120篇 |
1980年 | 116篇 |
1979年 | 97篇 |
1978年 | 96篇 |
1977年 | 106篇 |
1976年 | 82篇 |
1975年 | 61篇 |
1974年 | 66篇 |
1973年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
Anela Stanic Denis Rybin Francis Cannata Carole Hohl Jennifer Brody Jessie Gaeta 《AIDS care》2021,33(1):1-9
ABSTRACT The lack of stable housing can impair access and continuity of care for patients living with human immunodeficiency virus (HIV). This study investigated the relationship between housing status assessed at multiple time points and several core HIV-related outcomes within the same group of HIV patients experiencing homelessness. Patients with consistently stable housing (CSH) during the year were compared to patients who lacked CSH (non-CSH group). The study outcomes included HIV viral load (VL), CD4 counts, and health care utilization. Multivariable and propensity weighted analyses were used to assess outcomes adjusting for potential group differences. Of 208 patients, 88 (42%) had CSH and 120 (58%) were non-CSH. Patients with CSH had significantly higher proportion of VL suppression and higher mean CD4 counts. The frequency of nurse visits in the CSH group was less than a half of that in the non-CSH group. Patients with CSH were less likely to be admitted to the medical respite facility, and if admitted, their length of stay was about a half of that for the non-CSH group. Our study findings show that patients with CSH had significantly better HIV virologic control and immune status as well as improved health care utilization. 相似文献
3.
4.
Caryn Wujanto Jeremy Tey David Chia Francis Ho Kiat Huat Ooi Alvin S. Wong Yu Yang Soon Keith Lim 《Journal of Geriatric Oncology》2019,10(2):292-297
Background
Muscle invasive bladder cancer (MIBC) is prevalent in the older patients, who are a vulnerable population with multiple co-morbidities and at increased risk of complications. Radical cystectomy is often not suitable, hence radical radiotherapy (RT) is an alternative option. We reviewed the outcomes of older patients treated with RT with or without concurrent chemotherapy (CRT) at our institution.Methods
We retrospectively reviewed patients aged 65?years and above treated with radical RT for MIBC at our institution between March 2002 to January 2017. Data was collected from institutional medical records and RT databases. The primary outcome was 2- and 5-year overall survival (OS), recurrence free survival (RFS), and toxicities. Univariate cox proportional hazard regression models were performed to identify independent factors with significant impact on survival.Results
We identified 45 patients (34 males, 11 females) with a median age of 77?years (range 65–95). All patients received maximal transurethral resection of the bladder tumour prior to RT. Median dose of total RT was 64?Gy (range 50–69.8?Gy). Twenty one patients (47%) received CRT. Planned treatment was completed in 42 (93.3%) patients. Median follow-up was 31?months (range 1–147?months). The 2- and 5-year OS was 64% and 44%, respectively. The 2- and 5-year RFS was 68% and 49%, respectively. Median RFS was 34?months (range 8–121?months). Median OS was 56?months (range 18–100?months). Univariate analysis showed that performance status (0–1 vs. 2–3; HR 2.7, 95% CI 1.07–6.8, p?=?0.035) and International Society of Geriatric Oncology (SIOG) group (≤2 vs. >2; HR 3.23, 95% CI 1.12–8.64, p?=?0.019) were significantly associated with increased hazard for death. One patient (2%) had grade 3 cystitis.Conclusion
Radical RT is well tolerated in older patients with MIBC. We report outcomes similar to published data. Older patients should be considered for curative treatment despite their age. However, careful selection is warranted as frail patients (PS ≥2; SIOG >2) may benefit less. 相似文献5.
Bernard Natukunda Grace Ndeezi Lay See Er Francis Bajunirwe Gayle Teramura Meghan Delaney 《ISBT科学丛刊》2019,14(4):366-373
6.
Francis Brandon A. Fillenworth Jennifer Gorelick Philip Karanec Kristina Tanner Adriana 《Neurocritical care》2019,30(3):652-657
Neurocritical Care - Status, refractory status and super refractory status epilepticus are common neurologic emergencies. The objective of this study is to investigate the feasibility, safety and... 相似文献
7.
Erik C. von Rosenvinge Francis Palumbo Jacques Ravel Virginia Rowthorn Diane Hoffmann 《Gut microbes》2019,10(2):113-114
This is a reply to the commentary of Ossorio and Zhou. 相似文献
8.
9.
Lauren A. Eberly Emmanuel Rusingiza Paul H. Park Gedeon Ngoga Symaque Dusabeyezu Francis Mutabazi Cyprien Gahamanyi Evariste Ntaganda Gene F. Kwan Gene Bukhman 《Journal of the American College of Cardiology》2019,73(8):977-980
Nurse-led delivery care models have the potential to address the significant burden of heart failure in sub-Saharan Africa. Starting in 2006, the Rwandan Ministry of Health, supported by Inshuti Mu Buzima (Partners In Health–Rwanda), decentralized heart failure diagnosis and care delivery in the context of advanced nurse-led integrated noncommunicable clinics at rural district hospitals. Here, the authors describe the first medium-term survival outcomes from the district level in rural sub-Saharan Africa based on their 10-year experience providing care in rural Rwanda. Kaplan-Meier methods were used to determine median time to event for: 1) composite event of known death from any cause, lost to follow-up, or transfer to estimate worst-case mortality; and 2) known death only. Five-year event-free rates were 41.7% for the composite outcome and 64.3% for known death. While death rates are encouraging, efforts to reduce loss to follow-up are needed. 相似文献
10.
Ritu R. Gill Anne S. Tsao Hedy L. Kindler William G Richards Samuel G. Armato Roslyn J. Francis Daniel R. Gomez Suzanne Dahlberg Andreas Rimner Charles B. Simone Marc de Perrot Gideon Blumenthal Alex A. Adjei Raphael Bueno David H. Harpole Mary Hesdorffer Fred R. Hirsch Harvey I. Pass Anna K. Nowak 《Journal of thoracic oncology》2019,14(10):1718-1731
Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials. 相似文献